UA111914U - METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS - Google Patents

METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS

Info

Publication number
UA111914U
UA111914U UAU201605435U UAU201605435U UA111914U UA 111914 U UA111914 U UA 111914U UA U201605435 U UAU201605435 U UA U201605435U UA U201605435 U UAU201605435 U UA U201605435U UA 111914 U UA111914 U UA 111914U
Authority
UA
Ukraine
Prior art keywords
breast cancer
cancer patients
metastasation
mir
method formation
Prior art date
Application number
UAU201605435U
Other languages
Ukrainian (uk)
Inventor
Василь Федорович Чехун
Наталія Юріївна Лук'янова
Ірина Віталіївна Шепеленко
Дмитро Валерійович Демаш
Тетяна Вікторівна Борікун
Олександр Миколайович Клюсов
Микола Федорович Анікусько
Original Assignee
Інститут Експериментальної Патології, Онкології І Радіобіології Ім. Р.Є. Кавецького Нан України
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Інститут Експериментальної Патології, Онкології І Радіобіології Ім. Р.Є. Кавецького Нан України filed Critical Інститут Експериментальної Патології, Онкології І Радіобіології Ім. Р.Є. Кавецького Нан України
Priority to UAU201605435U priority Critical patent/UA111914U/en
Publication of UA111914U publication Critical patent/UA111914U/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Спосіб прогнозування метастазування у хворих на рак молочної залози з верифікованим діагнозом, у якому перед проведенням комплексного лікування у сироватці крові хворих визначають рівень мікроРНК-34а та мікроРНК-155. При рівнях мікроРНК-34а вище 2,5 ум. од. та мікроРНК-155 вище 0,9 ум. од. роблять висновок щодо наявності метастазів.Method for predicting metastasis in breast cancer patients with a verified diagnosis, in which the level of miR-34a and miR-155 is determined before conducting complex treatment in the blood of patients. At levels of miR-34a above 2.5 um. units and miR-155 above 0.9 μm. units make a conclusion about the presence of metastases.

UAU201605435U 2016-05-19 2016-05-19 METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS UA111914U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201605435U UA111914U (en) 2016-05-19 2016-05-19 METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201605435U UA111914U (en) 2016-05-19 2016-05-19 METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS

Publications (1)

Publication Number Publication Date
UA111914U true UA111914U (en) 2016-11-25

Family

ID=57792386

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201605435U UA111914U (en) 2016-05-19 2016-05-19 METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS

Country Status (1)

Country Link
UA (1) UA111914U (en)

Similar Documents

Publication Publication Date Title
CL2016000354A1 (en) Modulation of tumor immunity
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
GB2538178A (en) Viscosifier polymer for treatment of a subterranean formation
CL2015002223A1 (en) Therapeutic and diagnostic objective.
NZ720626A (en) Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers
MX2022008868A (en) Treatment of cancer with tg02.
AR096089A1 (en) FLOOD OPERATIONS THAT USE CHLORINE DIOXIDE
EA201790211A1 (en) METHOD FOR PREDICTING THE RESULTS OF THE TREATMENT OF AFLIBERCEPT PATIENTS PREFERREDLY SUFFERING FROM CANCER
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
GB2555019A (en) Apparatus and methods to manage wellbore fluid properties
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EA201790769A1 (en) DETERMINATION OF THE LEVELS OF GLYCOSAMINOGLICANES BY THE MASS SPECTROMETRY METHOD
EA201790019A1 (en) METHOD OF SELECTING PERSONALIZED THREE-COMPONENT TREATMENT FOR CANCER TREATMENT
BR112015023510A2 (en) Method for the diagnosis, prognosis and treatment of metastatic cancer
EA201890442A1 (en) OBTAINING PHOTORECEPTORS FOR THE TREATMENT OF RETITAL DISEASES
EA201790444A1 (en) HSP90-directed visualization and inflammation therapy and infection
BR112015014195A2 (en) method
MX2016006584A (en) Methods and compositions for treating amyloid deposits.
MX2017010516A (en) Biomarkers for diagnosis and prognosis of corneal ectatic disorders.
BR112016015595A2 (en) lung cancer determination methods
UA111914U (en) METHOD FORMATION OF METASTASATION IN BREAST CANCER PATIENTS
MX2017003015A (en) A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof.
BR112017016014A2 (en) method for treating an underground formation, system for performing the method for treating an underground formation, system, composition for the treatment of an underground formation, drilling fluid composition for the treatment of an underground formation and method for preparing a composition for the treatment of an underground formation
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE